×
About 6,168 results

ALLMedicine™ Hyperthyroidism Center

Research & Reviews  1,905 results

Lidocaine in ERAS for FESS
https://clinicaltrials.gov/ct2/show/NCT03047070

Jan 14th, 2022 - Functional endoscopic sinus surgery (FESS) is a commonly performed procedure in the head and neck field. It is known that bleeding during FESS can affect directly to the visibility of safe landmarks and surgical outcomes. Use of vasoactive drugs t...

Hyperthyroidism in Graves' disease causes sleep disorders related to sympathetic hypert...
https://doi.org/10.1210/clinem/dgac013
The Journal of Clinical Endocrinology and Metabolism; Matsumoto K, Izawa S et. al.

Jan 14th, 2022 - It is well known that Graves' disease (GD) causes sleep disorders (SD). However, the characteristics and associated factors of SD and its clinical course post-hyperthyroidism normalization remain unclear. To clarify the characteristics and associa...

Thyroid Scintigraphy of a Rare Case of Left Thyroid Lobe Hemiagenesis With Subacute Thy...
https://doi.org/10.1097/RLU.0000000000004017
Clinical Nuclear Medicine; Reya N, Posocco D et. al.

Jan 14th, 2022 - Thyroid hemiagenesis is a rare developmental anomaly. Patients with thyroid hemiagenesis have higher incidence of coexisting thyroid disorders in the remaining lobe. We present a rare case of a 21-year-old woman with subclinical hyperthyroidism in...

Autoimmune Thyroid Disease and Pregnancy
https://emedicine.medscape.com/article/261913-overview

Jan 13th, 2022 - Practice Essentials Thyroid disorders are the second most common endocrinologic disorders found in pregnancy. Overt hypothyroidism is estimated to occur in 0.3-0.5% of pregnancies. Subclinical hypothyroidism appears to occur in 2-3%, and hyperthyr...

123I Scintigraphy Mirror Image of Graves Disease Induced by Radioiodine Treatment for T...
https://doi.org/10.1097/RLU.0000000000003884
Clinical Nuclear Medicine; Lugat A, Drui D et. al.

Jan 11th, 2022 - A 61-year-old woman presenting with hyperthyroidism received 131I therapy for a toxic adenoma diagnosed by 123I scintigraphy. Six months later, the patient had a relapse of hyperthyroidism, and 123I scintigraphy showed a mirror image of the first ...

see more →

Guidelines  4 results

AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY...
https://doi.org/10.4158/EP151038.PS
Endocrine Practice : Official Journal of the American Col... Hennessey JV, Garber JR et. al.

Feb 6th, 2016 - Hypothyroidism and hyperthyroidism can be readily diagnosed and can be treated in a safe, cost-effective manner. Professional organizations have given guidance on how and when to employ thyroid-stimulating hormone testing for the detection of thyr...

American Thyroid Association Guide to investigating thyroid hormone economy and action ...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3887458
Thyroid : Official Journal of the American Thyroid Associ... Bianco AC, Anderson G et. al.

Sep 5th, 2013 - An in-depth understanding of the fundamental principles that regulate thyroid hormone homeostasis is critical for the development of new diagnostic and treatment approaches for patients with thyroid disease. Important clinical practices in use tod...

Hyperthyroidism and other causes of thyrotoxicosis: management guidelines of the Americ...
https://doi.org/10.4158/ep.17.3.456
Endocrine Practice : Official Journal of the American Col... Bahn RS, Burch HB et. al.

Jun 28th, 2011 - Thyrotoxicosis has multiple etiologies, manifestations, and potential therapies. Appropriate treatment requires an accurate diagnosis and is influenced by coexisting medical conditions and patient preference. This article describes evidence-based ...

Hyperthyroidism and other causes of thyrotoxicosis: management guidelines of the Americ...
https://doi.org/10.1089/thy.2010.0417
Thyroid : Official Journal of the American Thyroid Associ... Bahn Chair RS, Burch HB et. al.

Apr 23rd, 2011 - Thyrotoxicosis has multiple etiologies, manifestations, and potential therapies. Appropriate treatment requires an accurate diagnosis and is influenced by coexisting medical conditions and patient preference. This article describes evidence-based ...

see more →

Drugs  139 results see all →

Clinicaltrials.gov  51 results

Lidocaine in ERAS for FESS
https://clinicaltrials.gov/ct2/show/NCT03047070

Jan 14th, 2022 - Functional endoscopic sinus surgery (FESS) is a commonly performed procedure in the head and neck field. It is known that bleeding during FESS can affect directly to the visibility of safe landmarks and surgical outcomes. Use of vasoactive drugs t...

Effect of Small-volume Oral Spray in the After Anesthesia Recovery Room for Thirst Patients
https://clinicaltrials.gov/ct2/show/NCT05172648

Dec 29th, 2021 - Research design and research subjects use surveymonkey's sample number calculator to set the total number of patients in the year before inclusion and exclusion as the mother population: 5600, the verification power is set to 0.8, the effect is se...

Radiofrequency Ablation Versus I-131 for Solitary Autonomous Thyroid Nodules
https://clinicaltrials.gov/ct2/show/NCT05142904

Dec 3rd, 2021 - The purpose of this study is to compare treatment of hyperthyroidism with radiofrequency ablation or I-131 for solitary autonomous thyroid nodules.

The Prevalence and Risk Factors for Thyroid Dysfunction in Pregnant Women in Taiwan
https://clinicaltrials.gov/ct2/show/NCT04936698

Aug 16th, 2021 - The investigators' aim is to enroll around 2000 patients from Taipei, Keelung, Linkou, Chiayi and Kaohsiung CGMH. All participants will receive universal thyroid function screening at 1st trimester, and those who was found to have hyperthyroidism ...

Pattern and Frequency of Non-epileptic Involuntary Movements
https://clinicaltrials.gov/ct2/show/NCT04083586

Aug 9th, 2021 - Movement disorders are conventionally divided into major categories: 1) Hyperkinetic movement disorders (also called dyskinesias) refer to excessive, often repetitive, involuntary movements that intrude into the normal flow of motor activity. This...

see more →

News  336 results

Advanced Cervical Cancer: Toxicity Management With Balstilimab + Zalifrelimab
https://www.onclive.com/view/advanced-cervical-cancer-toxicity-management-with-balstilimab-zalifrelimab

Nov 30th, 2021 - Transcript: Robert L. Coleman, MD, FACOG, FACS: With respect to adverse events, we fortunately have the benefit of time and experience. When these drugs were first introduced into solid tumor therapy, we were very nervous about the toxicities we ...

Pembrolizumab/Axitinib Improves Outcomes in Japanese mRCC Subgroup
https://www.onclive.com/view/pembrolizumab-axitinib-improves-outcomes-in-japanese-mrcc-subgroup

Nov 30th, 2021 - The combination of pembrolizumab (Keytruda) and axitinib (Inlyta) demonstrated comparable activity and safety vs sunitinib (Sutent) in Japanese patients vs the global population of patients with newly diagnosed metastatic renal cell carcinoma (mRC...

Progress Made Across Breast Cancer Paradigm Sets the Stage for Improved Sequencing and Future Research
https://www.onclive.com/view/progress-made-across-breast-cancer-paradigm-sets-the-stage-for-improved-sequencing-and-future-research

Nov 18th, 2021 - Across all breast cancer subtypes, substantial progress with novel therapies has been made to improve outcomes for patients, determine optimal sequencing in earlier-stage disease, and spark ongoing research efforts featuring these newer agents, sa...

A Thyroid Antibody Primer in Five Quick Cases
https://www.medscape.com/viewarticle/962626

Nov 15th, 2021 - Hypothyroidism and hyperthyroidism are common and often the result of thyroid autoimmunity. The widespread availability of serum thyroid antibody laboratory testing may prompt questions from patients and clinicians. What do thyroid antibodies real...

Adjuvant Pembrolizumab Maintains RFS Benefit in Resected High-Risk Stage II Melanoma
https://www.onclive.com/view/adjuvant-pembrolizumab-maintains-rfs-benefit-in-resected-high-risk-stage-ii-melanoma

Nov 2nd, 2021 - Adjuvant pembrolizumab (Keytruda) continued to showcase improved relapse-free survival (RFS) over placebo in patients with resected high-risk stage II melanoma, according to findings from the second interim analysis of the phase 3 KEYNOTE-716 tria...

see more →

Patient Education  32 results see all →